<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE resolution PUBLIC "-//US Congress//DTDs/res.dtd//EN" "res.dtd">
<resolution resolution-stage="Reported-in-House" dms-id="H059C9B6F5C014CD9BAA866F6DCE54E62" public-private="public" resolution-type="house-resolution" star-print="no-star-print" key="H"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HRES 1287 RH: Of inquiry directing the President to provide certain documents in the President’s possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-09-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IV</distribution-code><calendar display="yes">House Calendar No. 144</calendar><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. RES. 1287</legis-num><associated-doc role="report" display="yes">[Report No. 117–538]</associated-doc><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220726">July 26, 2022</action-date><action-desc><sponsor name-id="W000798">Mr. Walberg</sponsor> submitted the following resolution; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><action display="yes"><action-date date="20220930">September 30, 2022</action-date><action-desc>Reported from the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>; referred to the House Calendar and ordered to be printed</action-desc></action><legis-type>RESOLUTION</legis-type><official-title display="yes">Of inquiry directing the President to provide certain documents in the President’s possession to the House of Representatives relating to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain.</official-title></form><resolution-body style="traditional" id="H75798A48583E485A9F8B1FE23CA8102C"><section display-inline="yes-display-inline" section-type="undesignated-section" id="H55DF324AAE5F4EFFBD19DB33FE19EA06"><enum/><text display-inline="yes-display-inline">That not later than 14 days after the adoption of this resolution, the President is directed to furnish to the House of Representatives copies of any document or record, audio recording, memorandum, call log, correspondence (electronic or otherwise), or other communication in the President’s possession (or any portion thereof), that refers or relates to the following:</text><paragraph id="HF300C774C12D4191A8C2B6795EBA0550"><enum>(1)</enum><text display-inline="yes-display-inline">the memoranda and report referenced in the testimony given by Dr. Robert Califf on May 25, 2022, during the hearing related to the recall of infant formula manufactured by Abbott Laboratories and potential impacts on the infant formula supply chain held by the Committee on Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce of the House of Representatives;</text></paragraph><paragraph id="H98C77C5763F74A4C83794637F803573B"><enum>(2)</enum><text display-inline="yes-display-inline">all communications between the Commissioner of Food and Drugs and other staff of the Food and Drug Administration and the White House regarding the infant formula recall and potential impact during or before February 2022;</text></paragraph><paragraph id="H4BC5767E0AC94B4CA3FC915776EE58B4"><enum>(3)</enum><text display-inline="yes-display-inline">the failure of the Food and Drug Administration to ensure the whistleblower complaint submitted to the Food and Drug Administration by an employee of Abbott Laboratories was sent to all necessary and appropriate officials and what actions the Food and Drug Administration has taken to prevent such a failure from happening in the future;</text></paragraph><paragraph id="HB38A683224864AF585AEFEFC8891A040"><enum>(4)</enum><text display-inline="yes-display-inline">the number of full-time equivalent positions in the Office of Regulatory Affairs of the Food and Drug Administration that remain vacant for food safety compliance and inspection staff;</text></paragraph><paragraph id="H29132C038C324877B13DD11C38DE7D7B"><enum>(5)</enum><text display-inline="yes-display-inline">all communications between the Food and Drug Administration and the Department of Agriculture about the recall of infant formula manufactured by Abbott Laboratories and the potential impact on the Special Supplemental Nutrition Program for Women, Infants, and Children, including the timing of such communications; and</text></paragraph><paragraph id="H090A15BD5C9345FBBC383C8CEFC304FB"><enum>(6)</enum><text display-inline="yes-display-inline">the number of submissions pending at the Food and Drug Administration as of the date of the adoption of this resolution for the marketing of infant formula, delineated by domestic and foreign manufacturers. </text></paragraph></section></resolution-body><endorsement display="yes"><action-date date="20220930">September 30, 2022</action-date><action-desc>Referred to the House Calendar and ordered to be printed</action-desc></endorsement></resolution> 

